MedWatch http://medwatch.dk/ MedWatch da Copyright 2012, MedWatch Wed, 26 Apr 2017 14:38:02 GMT MedWatch - seneste nyt MedWatch - seneste nyt medwatch.dk 2017-04-26T14:38:02Z da Copyright 2012, MedWatch MedWatch http://medwatch.dk/mwimg/logo/main_logo.png http://medwatch.dk/ Novo cancels antibody collaboration http://medwatch.dk/secure/Top_picks_in_english/article9531671.ece?utm_source=Feed&utm_medium=latest Novo Nordisk has annulled a billion dollar agreement for the development of antibodies for diabetes therapy. According to an analyst, there are two possible reasons why. Top picks in English Wed, 26 Apr 2017 14:38:02 GMT http://medwatch.dk/secure/Top_picks_in_english/article9531671.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-04-26T14:38:02Z true Zealand Pharma preparing for US expansion http://medwatch.dk/secure/Top_picks_in_english/article9531299.ece?utm_source=Feed&utm_medium=latest The top management in Zealand Pharma is on a charm offensive in the US where the Danish biotech company is planning to soon settle permanently. Top picks in English Wed, 26 Apr 2017 14:06:55 GMT http://medwatch.dk/secure/Top_picks_in_english/article9531299.ece?utm_source=Feed&utm_medium=latest BY LEONORA BECK 2017-04-26T14:06:55Z true GSK wants to revolutionize HIV therapy http://medwatch.dk/secure/Top_picks_in_english/article9529057.ece?utm_source=Feed&utm_medium=latest With its most promising HIV drug so far, GlaxoSmithKline now wants to lead a medical paradigm shift in HIV therapy and reduce the amount of drugs a patient has to take. Top picks in English Wed, 26 Apr 2017 13:13:07 GMT http://medwatch.dk/secure/Top_picks_in_english/article9529057.ece?utm_source=Feed&utm_medium=latest BY LOUISE WENDT JENSEN 2017-04-26T13:13:07Z true Alligator is still hungry following major milestones http://medwatch.dk/secure/Top_picks_in_english/article9530822.ece?utm_source=Feed&utm_medium=latest With a successful IPO and a lucrative partnership deal with Janssen under its belt, Sunstone-backed Alligator Biosciences is turning its focus on its proprietary pipeline and three promising candidate drugs. Top picks in English Wed, 26 Apr 2017 12:41:19 GMT http://medwatch.dk/secure/Top_picks_in_english/article9530822.ece?utm_source=Feed&utm_medium=latest BY ELIZABETH MØNSTED JOHANSEN 2017-04-26T12:41:19Z true Novo invests millions in new NASH player http://medwatch.dk/secure/Top_picks_in_english/article9528680.ece?utm_source=Feed&utm_medium=latest Novo Ventures has taken the lead in a Series A financing round in a new US-based company developing medicine against the liver disease NASH – a disease that big as well as small companies have started to focus on, including Novo Nordisk. Top picks in English Wed, 26 Apr 2017 12:05:56 GMT http://medwatch.dk/secure/Top_picks_in_english/article9528680.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-04-26T12:05:56Z true Suppliers expect continued growth http://medwatch.dk/secure/Top_picks_in_english/article9531104.ece?utm_source=Feed&utm_medium=latest Danish suppliers of diagnostics and laboratory equipment expect a lot of progress in 2017, but a new report shows that the expectations differ from sector to sector. Top picks in English Wed, 26 Apr 2017 11:56:44 GMT http://medwatch.dk/secure/Top_picks_in_english/article9531104.ece?utm_source=Feed&utm_medium=latest BY SØREN DURAN DUUS 2017-04-26T11:56:44Z true Saniona obtains research milestone from Hollywood celebrity’s fund http://medwatch.dk/secure/Top_picks_in_english/article9528218.ece?utm_source=Feed&utm_medium=latest The Danish biotech company Saniona receives their second milestone payment from The Michael J. Fox Foundation for Parkinson's Research after making new progress in the research on potential candidate drugs against Parkinson’s Disease. Top picks in English Tue, 25 Apr 2017 11:22:25 GMT http://medwatch.dk/secure/Top_picks_in_english/article9528218.ece?utm_source=Feed&utm_medium=latest BY ELIZABETH MØNSTED JOHANSEN 2017-04-25T11:22:25Z true Global venture boss keeps an eye on Danish biotech companies http://medwatch.dk/secure/Top_picks_in_english/article9514452.ece?utm_source=Feed&utm_medium=latest Omega Funds receives 2200 applications from life science companies per year and 99.9 percent of these are turned down. But some Danish biotech companies have caught the attention of founder Otello Stampacchia and might be among the 0.1 lucky ones. Top picks in English Wed, 19 Apr 2017 19:47:08 GMT http://medwatch.dk/secure/Top_picks_in_english/article9514452.ece?utm_source=Feed&utm_medium=latest BY LEONORA BECK 2017-04-19T19:47:08Z true AstraZeneca sees great success with unique incubator http://medwatch.dk/secure/Top_picks_in_english/article9512728.ece?utm_source=Feed&utm_medium=latest In the aftermath of the consolidation of its research and development activities, AstraZeneca has launched a new business incubator in Sweden. The project is partly state-funded and the drug company is very interested in welcoming Danish companies. Top picks in English Wed, 19 Apr 2017 19:41:11 GMT http://medwatch.dk/secure/Top_picks_in_english/article9512728.ece?utm_source=Feed&utm_medium=latest BY ELIZABETH MØNSTED JOHANSEN 2017-04-19T19:41:11Z true ALK-director: Important strategic approval http://medwatch.dk/secure/Top_picks_in_english/article9514712.ece?utm_source=Feed&utm_medium=latest With the expansion of the indication for their house dust mite pill, which now also covers the age range from 12-17 years, ALK gets access to a strategically important market segment. Top picks in English Wed, 19 Apr 2017 12:38:27 GMT http://medwatch.dk/secure/Top_picks_in_english/article9514712.ece?utm_source=Feed&utm_medium=latest BY LOUISE WENDT JENSEN 2017-04-19T12:38:27Z true Bavarian Nordic signs new commercial agreement http://medwatch.dk/secure/Top_picks_in_english/article9514795.ece?utm_source=Feed&utm_medium=latest The Danish biotech company enters into a partnership with French counterpart which ensures Bavarian Nordic the rights to develop and commercialize new poxvirus-based vaccines. Top picks in English Wed, 19 Apr 2017 12:32:50 GMT http://medwatch.dk/secure/Top_picks_in_english/article9514795.ece?utm_source=Feed&utm_medium=latest BY SØREN DURAN DUUS 2017-04-19T12:32:50Z true BMS signs fibrosis deal with Danish biotech company http://medwatch.dk/secure/Top_picks_in_english/article9512491.ece?utm_source=Feed&utm_medium=latest A Danish biotech company is now going to develop biomarkers for US-based drug group Bristol-Myers Squibb to potentially aid in diagnosing and monitoring fibrotic diseases, including fatty liver disease NASH. Top picks in English Tue, 18 Apr 2017 13:38:14 GMT http://medwatch.dk/secure/Top_picks_in_english/article9512491.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-04-18T13:38:14Z true Novo A/S invests billions in laboratory company http://medwatch.dk/secure/Top_picks_in_english/article9512035.ece?utm_source=Feed&utm_medium=latest For the third time, Novo A/S invests in Synlab, Europe’s biggest company for laboratory analyses. Previously, Novo A/S has not wanted to disclose the amount invested. But this time, the investment sum is revealed and it amounts to billions of Danish kroner. Top picks in English Tue, 18 Apr 2017 12:30:54 GMT http://medwatch.dk/secure/Top_picks_in_english/article9512035.ece?utm_source=Feed&utm_medium=latest BY LONNI LYNGE 2017-04-18T12:30:54Z true